Bharat Biotech confirms agreement with Brazil to supply 20 million doses of COVAXIN

“The company has signed an agreement for the delivery of COVAXIN®️ during Q2 and Q3 2021. The company is delighted to partner with Brazil in its battle against Covid-19 and to help its vaccine program against the virus “Bharat Biotech said in a statement.

There is strong interest in COVAXIN®️ from many countries around the world, and the company is fully committed to securing supplies quickly and efficiently, he added.

Krishna Ella, chairman and managing director of Bharat Biotech recently said the Hyderabad-based vaccine maker will commission its third facility by the end of this week and then be able to produce at least 40 million. doses of the vaccine each month. . He said the increased production of the vaccine will potentially help reduce the global shortage.

Bharat Biotech also announced earlier this month that it has signed a pact with Ocugen Inc, allowing the US-based biopharmaceutical company to co-develop, supply and market the Covid-19 vaccine from Indian vaccine maker Covaxin. in the US market. In agreement, Ocugen will own the commercial rights to the vaccine candidate in the United States and will be responsible for conducting clinical trials and obtaining emergency use authorization (EUA) from the US Food and Drug Administration.

In indicating a step towards the Covaxin vaccine as a viable option to fight the pandemic, opening up new markets, the company also sought permission from the governments of Bangladesh and Myanmar to conduct clinical trials.

Bharat Biotech in India had obtained an emergency license from the Comptroller General of Drugs of India VG Somani for its fully inactivated SARS-COV2 vaccine despite the lack of efficacy data, after which the vaccine administration was started Jan. 16. The company has announced that it will release the first set of interim data on the effectiveness of Covaxin from its ongoing Phase 3 trials in two weeks.